NEW YORK – Cancer diagnostic testing firm Pillar Biosciences announced Tuesday that it has closed a $29.7 Series C preferred stock financing round led by ORI Healthcare Fund. It also announced CE marking for its Onco/Reveal Dx lung and colon cancer in vitro diagnostic assay.
The Natick, Massachusetts-based assay developer said it will use the funds to accelerate expansion of its clinical and research-use next-generation sequencing panels and to expand its global commercial reach.